[go: up one dir, main page]

MA27749A1 - 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose - Google Patents

2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose

Info

Publication number
MA27749A1
MA27749A1 MA28502A MA28502A MA27749A1 MA 27749 A1 MA27749 A1 MA 27749A1 MA 28502 A MA28502 A MA 28502A MA 28502 A MA28502 A MA 28502A MA 27749 A1 MA27749 A1 MA 27749A1
Authority
MA
Morocco
Prior art keywords
compound
sulfonylamino
pyridin
propyl
butyl
Prior art date
Application number
MA28502A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Goegellein
Klaus Wirth
Gert Ulrich Kuerzel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27749A1 publication Critical patent/MA27749A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne le composé 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-méthoxy-pyridin-3-yl)-propyl]-benzamide représenté par la formule (I), ainsi que les sels pharmaceutiquement acceptables de ce composé. L'invention concerne en outre la production et l'utilisation de ce composé ou de ses sels pharmaceutiquement acceptables, notamment en traitement et prévention d'arythmies auriculaires, par exemple de la fibrillation auriculaire (fïbrillation atriale) ou du flutter auriculaire (flutter atrial).
MA28502A 2003-03-18 2005-09-19 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose MA27749A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
MA27749A1 true MA27749A1 (fr) 2006-02-01

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28502A MA27749A1 (fr) 2003-03-18 2005-09-19 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose

Country Status (22)

Country Link
EP (1) EP1606237A1 (fr)
JP (1) JP2006520343A (fr)
KR (1) KR20050110681A (fr)
CN (1) CN100361943C (fr)
AR (1) AR043622A1 (fr)
AU (1) AU2004222137A1 (fr)
BR (1) BRPI0408441A (fr)
CA (1) CA2519022A1 (fr)
DE (1) DE10312073A1 (fr)
HK (1) HK1086819A1 (fr)
HR (1) HRP20050815A2 (fr)
MA (1) MA27749A1 (fr)
MX (1) MXPA05009763A (fr)
MY (1) MY176510A (fr)
NO (1) NO20054472L (fr)
NZ (1) NZ542476A (fr)
PE (1) PE20050307A1 (fr)
RS (1) RS20050690A (fr)
RU (1) RU2333202C2 (fr)
TW (1) TW200500342A (fr)
WO (1) WO2004083157A1 (fr)
ZA (1) ZA200506328B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
JP4943429B2 (ja) * 2005-07-22 2012-05-30 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
CN1756728A (zh) 2006-04-05
MXPA05009763A (es) 2006-01-27
EP1606237A1 (fr) 2005-12-21
PE20050307A1 (es) 2005-06-08
HK1086819A1 (en) 2006-09-29
BRPI0408441A (pt) 2006-04-04
AU2004222137A1 (en) 2004-09-30
RU2005132163A (ru) 2006-04-10
NO20054472L (no) 2005-09-27
AR043622A1 (es) 2005-08-03
HRP20050815A2 (en) 2006-09-30
MY176510A (en) 2020-08-12
CN100361943C (zh) 2008-01-16
JP2006520343A (ja) 2006-09-07
DE10312073A1 (de) 2004-09-30
KR20050110681A (ko) 2005-11-23
RS20050690A (sr) 2008-04-04
CA2519022A1 (fr) 2004-09-30
TW200500342A (en) 2005-01-01
RU2333202C2 (ru) 2008-09-10
WO2004083157A1 (fr) 2004-09-30
NZ542476A (en) 2008-05-30
ZA200506328B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
NO20034751L (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
BR0215777A (pt) Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
RU94044454A (ru) Ингибитор аутоимунных заболеваний
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
HUP0302068A2 (hu) COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények
DE60214569D1 (de) Harnstoffverbindungen mit antiproteolytischer wirkung
MA27749A1 (fr) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
WO2002064552A8 (fr) DERIVE DE α-AMINO-N-HYDROXY-ACETAMIDE
SE9901572D0 (sv) New compounds
SE0201837D0 (sv) Chemical compounds
GB9126874D0 (en) Medicaments
SE0103272D0 (sv) Chemical compounds